U.S. judge rejects Shkreli's request to delay $64.6 mln payment pending appeal - Reuters.com

WASHINGTON, March 17 (Reuters) - A federal judge on Thursday rejected Martin Shkreli's request to delay a $64.6 million payment while he appeals a loss to the Federal Trade Commission over whether he broke antitrust law while sharply pushing up the price of a life-saving drug.

U.S. District Judge Denise Cote in Manhattan had ruled in January for the FTC and seven states that accused Shkreli, the founder of Vyera Pharmaceuticals, of using illegal tactics to keep rivals out of the market while raising the price of the drug Daraprim to $750 per tablet from $17.50 in 2015.

She had also barred Shkreli, who is in prison, from the pharmaceutical industry for life. read more Another judge in February barred Shkreli from serving as an officer or director of a publicly traded company. read more

An FTC spokesperson said it was "pleased with the court's decision." Lawyers for Shkreli did not immediately respond to a request for comment.

Register now for FREE unlimited access to Reuters.com

Reporting by Diane Bartz and Jon Stempel; Editing by Chris Reese, Mark Porter and Richard Chang

Our Standards: The Thomson Reuters Trust Principles.

Adblock test (Why?)

U.S. judge rejects Shkreli's request to delay $64.6 mln payment pending appeal - Reuters.com
Read More